GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003133120 | Oral cavity | OSCC | positive regulation of cellular catabolic process | 273/7305 | 427/18723 | 6.39e-26 | 2.02e-23 | 273 |
GO:004217620 | Oral cavity | OSCC | regulation of protein catabolic process | 254/7305 | 391/18723 | 1.07e-25 | 3.22e-23 | 254 |
GO:004586220 | Oral cavity | OSCC | positive regulation of proteolysis | 236/7305 | 372/18723 | 6.53e-22 | 1.38e-19 | 236 |
GO:190382920 | Oral cavity | OSCC | positive regulation of cellular protein localization | 179/7305 | 276/18723 | 2.20e-18 | 2.41e-16 | 179 |
GO:00160508 | Oral cavity | OSCC | vesicle organization | 189/7305 | 300/18723 | 2.40e-17 | 2.14e-15 | 189 |
GO:004573220 | Oral cavity | OSCC | positive regulation of protein catabolic process | 150/7305 | 231/18723 | 1.06e-15 | 7.64e-14 | 150 |
GO:001703815 | Oral cavity | OSCC | protein import | 136/7305 | 206/18723 | 3.15e-15 | 2.08e-13 | 136 |
GO:00161979 | Oral cavity | OSCC | endosomal transport | 141/7305 | 230/18723 | 5.40e-12 | 2.06e-10 | 141 |
GO:00070327 | Oral cavity | OSCC | endosome organization | 59/7305 | 82/18723 | 1.41e-09 | 3.39e-08 | 59 |
GO:00325065 | Oral cavity | OSCC | cytokinetic process | 33/7305 | 39/18723 | 5.91e-09 | 1.26e-07 | 33 |
GO:00002815 | Oral cavity | OSCC | mitotic cytokinesis | 51/7305 | 71/18723 | 2.01e-08 | 3.95e-07 | 51 |
GO:003010016 | Oral cavity | OSCC | regulation of endocytosis | 121/7305 | 211/18723 | 4.74e-08 | 8.80e-07 | 121 |
GO:000091010 | Oral cavity | OSCC | cytokinesis | 97/7305 | 173/18723 | 3.82e-06 | 4.51e-05 | 97 |
GO:00616405 | Oral cavity | OSCC | cytoskeleton-dependent cytokinesis | 60/7305 | 100/18723 | 1.69e-05 | 1.67e-04 | 60 |
GO:00336194 | Oral cavity | OSCC | membrane protein proteolysis | 37/7305 | 57/18723 | 6.66e-05 | 5.38e-04 | 37 |
GO:00065094 | Oral cavity | OSCC | membrane protein ectodomain proteolysis | 29/7305 | 43/18723 | 1.49e-04 | 1.05e-03 | 29 |
GO:19038288 | Oral cavity | OSCC | negative regulation of cellular protein localization | 65/7305 | 117/18723 | 2.05e-04 | 1.36e-03 | 65 |
GO:0097320 | Oral cavity | OSCC | plasma membrane tubulation | 15/7305 | 20/18723 | 1.19e-03 | 5.99e-03 | 15 |
GO:00069072 | Oral cavity | OSCC | pinocytosis | 16/7305 | 22/18723 | 1.40e-03 | 6.79e-03 | 16 |
GO:20000093 | Oral cavity | OSCC | negative regulation of protein localization to cell surface | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNX33 | SNV | Missense_Mutation | | c.1559G>A | p.Cys520Tyr | p.C520Y | Q8WV41 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
SNX33 | SNV | Missense_Mutation | novel | c.805N>G | p.His269Asp | p.H269D | Q8WV41 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
SNX33 | SNV | Missense_Mutation | | c.656G>A | p.Arg219His | p.R219H | Q8WV41 | protein_coding | tolerated(0.54) | benign(0.223) | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SNX33 | insertion | In_Frame_Ins | novel | c.803_804insGGCTGCTAAGGGAGGAGG | p.Lys268_His269insAlaAlaLysGlyGlyGly | p.K268_H269insAAKGGG | Q8WV41 | protein_coding | | | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
SNX33 | insertion | Nonsense_Mutation | novel | c.695_696insAGCCCAGCTAGGAGTGGTGGGGGCAGTGGCTTCCT | p.Cys232Ter | p.C232* | Q8WV41 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | novel | c.5N>T | p.Ala2Val | p.A2V | Q8WV41 | protein_coding | deleterious(0) | possibly_damaging(0.516) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SNX33 | SNV | Missense_Mutation | rs765176187 | c.524N>A | p.Arg175Gln | p.R175Q | Q8WV41 | protein_coding | tolerated(0.25) | benign(0.06) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | | c.1593G>T | p.Met531Ile | p.M531I | Q8WV41 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | | c.797N>A | p.Arg266His | p.R266H | Q8WV41 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3667-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | | c.1146G>T | p.Lys382Asn | p.K382N | Q8WV41 | protein_coding | deleterious(0.01) | benign(0.444) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |